The ASCT Annual Conference is our principle venue for educating cytotechnologists, cytopathologists, lab managers, teachers, students and more in both the established and latest innovations in the profession. At the ASCT Conference, you will have a chance to visit with cytotechnology professionals and decision makers. The intimate size of our audience will guarantee plenty of one-on-one time with key clients. Your current and future customers will be at the ASCT Conference.
Exhibits are table top only. Includes: breakfast, morning and afternoon breaks in the exhibit hall Friday and Saturday, Friday evening Welcome Reception, signage in exhibit hall, company name on the ASCT website, and inclusion of contact information and product description in registration materials.The Exhibit Space will consist of tabletop exhibits. Each exhibitor will be provided with a six-foot table, two chairs and a wastebasket. Please plan on making arrangements for the set-up of your display, as there is no official decorator for this meeting.
Registration for two company representatives is included. Additional company representatives or guests may be registered for an additional fee of $100 per person.
For questions or more information, contact email@example.com.
Additional Sponsorship Opportunities
ASCT offers many different sponsorship opportunities. Have another idea of a sponsorship? Let us know!
- Friday Evening Welcome Reception
- Friday or Saturday Breakfast
- Morning or Afternoon Breaks
- Student Registration Sponsorship
- Conference Lanyards
- Sport Water Bottles
- Conference Pens
- Conference Bags
- Workshop Splash Page
- Hotel room key cards
Thank You 2021 Exhibitors!
ASCT Services, Inc.
ASCT SERVICES, INC. (Services) is a for-profit business created in 1998 under the auspices of the American Society for Cytotechnology (ASCT). ASCT Services has three decades of experience and accomplishments related to work requested by the Centers for Medicare and Medicaid Services (CMS) and other health organizations. Our efforts help ensure that the highest standards of cytology laboratory practice are maintained. We have completed nearly 1300 surveys with a team comprised of approximately 60 supervisory level cytotechnologists, seven (7) board-certified cytopathologists and eight (8) survey team leaders.
Our Mission: ASCT Services will offer products and services that improve patient care and benefit clients, cytology services, and the medical community in a technically sound and professional manner.
Bard1 Life Sciences
BARD1 Life Sciences Ltd (ASX:BD1) (BARD1 or the Company) is a leading Australian-based medical diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on the development and commercialization of best-in-class lifesaving diagnostic solutions for health care professionals and patients. The cancer diagnostics portfolio includes the marketed hTERT test to aid in the diagnosis of bladder cancer and tests in development for ovarian, breast, lung, prostate and pancreatic cancers.
CellSolutions develops high quality liquid based preparation and evaluation systems for cytology applications. Pending FDA-PMA approval, our primary area of focus will be women’s health, including cervical cancer screening, pre-cancer detection and evaluation of infectious disease. Currently, our products are suitable for a broad range of non-Gyn applications including urine and fine needle aspirations.
We offer a complete solution for your cytology needs, ranging from sample collection, preservation and slide preparation. Advanced image analysis and innovative slide evaluation technology is in the final stages of development and evaluation.
A special thanks to Hologic for their generous educational grant and Saturday morning break sponsorship.
We achieve this by bringing The Science of Sure® to life. The Science of Sure reflects who we are as a leading innovator in women’s health, helping healthcare professionals around the world diagnose and treat their patients with precision, certainty and confidence.
With groundbreaking technology at the core, our innovations are designed to achieve exceptional clinical results, making it possible to detect, diagnose and treat illnesses and other health conditions earlier and more effectively.
By providing early and accurate results, our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. Because when their health is in question, nothing is more important than being sure.
Interpace Diagnostics is a leading provider of molecular testing for thyroid nodules. Our unique dual-platform test utilizing ThyGeNEXT®, an oncogene mutation panel, and ThyraMIR®, a microRNA classifier, helps to overcome diagnostic uncertainty using our selected Markers That Matter.™
When used in combination, a 97% NPV and 75% PPV has been demonstrated within our clinical validation study where ThyGeNEXT + ThyraMIR accurately ruled-in or ruled-out disease in four out of five nodules tested—including RAS-positive nodules. This dual-platform testing has also been validated to accurately identify Medullary Thyroid Cancer. You can view these validation and other studies at https://thygenext-thyramir.com/evidence.
Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. With over 100 years of optical design expertise, Nikon offers industry-leading microscope systems for clinical pathology including digital pathology and remote slide viewing and sharing. See the difference with Nikon optics and digital solutions.
Praxis Medical Devices
Praxis Medical was founded by Dr. John Fisher MD in 2018. Dr. Fisher has spent the last 30 years leveraging his vast medical knowledge to innovate products that address unmet clinical needs for doctors, patients, and providers. He has served as the Chief of Interventional Radiology at Morton Plant Hospital for over 13 years and the CEO of Biopsy Sciences since 2000. At Biopsy Sciences he and his partners developed the HydroMark breast biopsy marker (acquired by Devicor in 2014), the Bio-SEAL biopsy tract sealant (now BioSentry acquired by Angiodynamics in 2018), and the Maxi-Cell needle (acquired by Angiotech in 2004).
At Praxis Medical, Dr. Fisher has developed CytoCore to revolutionize the soft tissue biopsy space.